Company: PSTV
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-178940
Chunk: 24

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: S-1
Chunk 24
---
 August 8, 2025,                                                                                                                                                      
 adjusted to include the number of shares set forth in the adjacent column which we would have sold to Lincoln Park, assuming the purchase price in the adjacent column, and the issuance of the Initial Commitment Shares. The numerator is based on the 
 number of shares issuable under the Purchase Agreement at the corresponding assumed purchase price set forth in the adjacent column and the number of Initial Commitment Shares, without giving effect to the Beneficial Ownership Cap.                  |

| (3) | The closing sale price per share of our common stock on August 8, 2025. |

13

USE OF PROCEEDS

This prospectus relates to shares of our common stock that may be offered and sold from time to time by Lincoln Park. We will receive no
proceeds from the sale of shares of common stock by Lincoln Park in this offering. We may receive up to $50.0 million in aggregate gross proceeds under the Purchase Agreement, of which $47.2 million remains to be purchased (initially
$25 million and if the full $25 million is purchased, then immediately and automatically up to an additional $25 million aggregate gross proceeds), from any sales we make to Lincoln Park pursuant to the Purchase Agreement. Assuming a
purchase price of $0.80 (which represents the closing price of our common stock on August 8, 2025), the purchase by Lincoln Park for cash of the entire 31,387,097 shares being registered for resale hereunder, which we have the right but not the
obligation to sell to Lincoln Park, would result in gross proceeds to us of approximately $25.1 million, and we estimate approximately $22.1 million of net proceeds, after estimated fees and expenses. See “Plan of Distribution” elsewhere
in this prospectus for more information.

On June 17, 2025, we entered into a letter agreement (the “Side Letter”) with
certain holders of our warrants issued on March 4, 2025. Pursuant to the Side Letter, among other things, such holders agreed to return the shares and pre-funded warrants issued to them on March 4,
2025 and we agreed to repay the holders holding such securities 115% of the value of such securities, using 90% of the proceeds from any capital raised by us subsequent to July 1, 2025 (the “Make-Whole Repayment”). The total amount of
the repayment as of the date of the